Meta-Analysis: Reduced Risk of Anxiety with Psychostimulant Treatment in Children with Attention-Deficit/Hyperactivity Disorder

Imagem de Miniatura
Arquivos
art_COUGHLIN_MetaAnalysis_Reduced_Risk_of_Anxiety_with_Psychostimulant_Treatment_2015.PDF (331.23 KB)
Citações na Scopus
48
Tipo de produção
article
Data de publicação
2015
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MARY ANN LIEBERT, INC
Autores
COUGHLIN, Catherine G.
COHEN, Stephanie C.
MULQUEEN, Jilian M.
STUCKELMAN, Zachary D.
BLOCH, Michael H.
Citação
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, v.25, n.8, p.611-617, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: Anxiety is a commonly reported side-effect of psychostimulant treatment. Our goal was to quantify the risk of anxiety as a side effect of psychostimulant treatment for attention-deficit/hyperactivity disorder (ADHD). Methods: We conducted a PubMed search to identify all double-blind, randomized, placebo-controlled trials examining the efficacy of psychostimulant medications in the treatment of children with ADHD. We used a fixed-effects meta-analysis to examine the risk ratio of anxiety reported as a side effect in children treated with psychostimulants compared with those treated with placebo. We used stratified subgroup analysis and meta-regression to examine the effects of stimulant type, dosage, duration of use, and trial design on the measured risk of anxiety. Results: We identified 23 studies involving 2959 children with ADHD for inclusion in our meta-analysis. The risk of anxiety associated with psychostimulant treatment was significantly lower than that experienced with placebo (relative risk [RR]=0.86 [95% CI: 0.77, 0.95], z=-2.90, p<0.05). Higher doses of psychostimulants were associated with a reduced measured risk of anxiety of psychostimulants when compared with placebo (=-0.0039 [95% CI: -0.00718, -0.00064], z=-2.34, p=0.019). Conclusions: Meta-analysis suggests that treatment with psychostimulants significantly reduced the risk of anxiety when compared with placebo. This finding does not rule out the possibility that some children experience increased anxiety when treated with psychostimulants, but suggests that those risks are outweighed by the number of children who experience improvement in anxiety symptoms (possibly as a secondary effect of improved control of ADHD symptoms). Clinicians should consider rechallenging children with ADHD who report new-onset or worsening anxiety with psychostimulants, as these symptoms are much more likely to be coincidental rather than caused by psychostimulants.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/12491
Referências
  1. RAPPORT MD, 1985, J ABNORM CHILD PSYCH, V13, P227, DOI 10.1007/BF00910644
  2. Wigal S, 2004, J AM ACAD CHILD PSY, V43, P1406, DOI 10.1097/01.chi.0000138351.98604.92
  3. GITTELMANKLEIN R, 1976, ARCH GEN PSYCHIAT, V33, P1217
  4. Feldman HM, 2014, NEW ENGL J MED, V370, P838, DOI 10.1056/NEJMcp1307215
  5. Stein MA, 2003, PEDIATRICS, V112, pE404, DOI 10.1542/peds.112.5.e404
  6. Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1088
  7. YOUNG R, 1991, PHARMACOL BIOCHEM BE, V40, P739, DOI 10.1016/0091-3057(91)90078-G
  8. Biederman J, 2002, PEDIATRICS, V110, P258, DOI 10.1542/peds.110.2.258
  9. March JS, 2000, J ABNORM CHILD PSYCH, V28, P527, DOI 10.1023/A:1005179014321
  10. Greenhill LL, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.3.e39
  11. Ter-Stepanian M, 2010, CAN J PSYCHIAT, V55, P305
  12. BUITELAAR JK, 1995, J AM ACAD CHILD PSY, V34, P1025, DOI 10.1097/00004583-199508000-00012
  13. BARKLEY RA, 1990, PEDIATRICS, V86, P184
  14. Solanto M, 2009, J CHILD ADOL PSYCHOP, V19, P663, DOI 10.1089/cap.2009.0033
  15. Egger M, 1997, BRIT MED J, V315, P629
  16. Bilkei-Gorzo A, 1998, PSYCHOPHARMACOLOGY, V136, P291, DOI 10.1007/s002130050568
  17. Wigal T, 2006, J AM ACAD CHILD PSY, V45, P1294, DOI 10.1097/01.chi.0000235082.63156.27
  18. Childress AC, 2009, J CHILD ADOL PSYCHOP, V19, P351, DOI 10.1089/cap.2009.0007
  19. Pliszka SR, 2000, J AM ACAD CHILD PSY, V39, P619, DOI 10.1097/00004583-200005000-00016
  20. Buitelaar JK, 1996, J CHILD PSYCHOL PSYC, V37, P587, DOI 10.1111/j.1469-7610.1996.tb01445.x
  21. WERRY JS, 1980, J CHILD PSYCHOL PSYC, V21, P27, DOI 10.1111/j.1469-7610.1980.tb00013.x
  22. AHMANN PA, 1993, PEDIATRICS, V91, P1101
  23. Stein MA, 1996, PEDIATRICS, V98, P748
  24. Spencer TJ, 2006, CLIN THER, V28, P266, DOI 10.1016/j.clinthera.2006.02.011
  25. McCracken JT, 2003, J AM ACAD CHILD PSY, V42, P673, DOI 10.1097/01.CH1.0000046863.56865.FE
  26. Golubchik P, 2014, INT CLIN PSYCHOPHARM, V29, P212, DOI 10.1097/YIC.0000000000000029
  27. Gorman EB, 2006, J AM ACAD CHILD PSY, V45, P808, DOI 10.1097/01.chi.0000214191.57993.dd
  28. Sciberras E, 2014, PEDIATRICS, V133, P801, DOI 10.1542/peds.2013-3686
  29. Liberati A, 2009, ANN INTERN MED, V151, pW65
  30. CONNERS CK, 1980, ARCH GEN PSYCHIAT, V37, P922
  31. Newcorn JH, 2008, AM J PSYCHIAT, V165, P721, DOI 10.1176/appi.ajp.2007.05091676
  32. Abikoff H, 2005, J AM ACAD CHILD PSY, V44, P418, DOI 10.1097/01.chi.0000155320.52322.37
  33. Firestone P, 1998, J CHILD ADOL PSYCHOP, V8, P13, DOI 10.1089/cap.1998.8.13
  34. Gillberg C, 1997, ARCH GEN PSYCHIAT, V54, P857
  35. Bloch Y, 2013, J ATTEN DISORD
  36. Lee J, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-70
  37. NextWave Pharmaceuticals, 2012, PROD INF QUILLIVANT
  38. Swenson M, STIMULANT EQUIVALENC
  39. United States Product Information, 2013, ADDERALL XR R OR CAP
  40. Weiss G, 1993, HYPERACTIVE CHILDREN

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - HC/ICHC